{
    "clinical_study": {
        "@rank": "70586", 
        "arm_group": {
            "arm_group_label": "Repeated GnRHa", 
            "arm_group_type": "Experimental", 
            "description": "Patients were triggered with repeated GnRHa"
        }, 
        "brief_summary": {
            "textblock": "Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte\n      maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian\n      hyperstimulation syndrome (OHSS) in high-risk patients.\n\n      However, lower oocyte yield was reported in patients with lower luteinizing hormone (LH)\n      level post trigger with single injection of GnRH agonist, which might be related to the\n      shorter duration and lower amount of LH induced by GnRH agonist.\n\n      Our aim is to study repeated injection of GnRH agonist for preventing OHSS and maintaining\n      clinical outcome in high risk patients who receive controlled ovarian stimulation in GnRH\n      antagonist protocol."
        }, 
        "brief_title": "Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility and at High Risk of OHSS", 
        "condition_browse": {
            "mesh_term": [
                "Infertility", 
                "Ovarian Hyperstimulation Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "This was a prospective cohort study of all women attending the Center for Reproductive\n      Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, affiliated with\n      Southern Medical University for in vitro fertilization and/or intracytoplasmic sperm\n      injection . Women at high risk of OHSS who received IVF and/or intracytoplasmic sperm\n      injection (ICSI) treatment with a flexible GnRH antagonist protocol were recruited to\n      participate in this study.\n\n      All patients underwent standard ovarian stimulation protocol with gonadotropins, standard\n      individualized adjustment of medication dose, and standard egg retrieval procedure. Patients\n      were triggered with a single bolus of 0.2 mg triptorelin at night and had second injection\n      of 0.2 mg triptorelin 12 hours later when the criteria for administration of the ovulation\n      trigger were met."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with polycystic ovarian syndrome\n\n          -  patients with polycystic ovarian morphology on ultrasound\n\n          -  patients who previously experienced an ovarian stimulation cycle, with a high\n             response to gonadotrophins\n\n        Exclusion Criteria:\n\n          -  patients undergoing coasting\n\n          -  patients with past ovarian surgery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022241", 
            "org_study_id": "Repeated GnRHa trigger"
        }, 
        "intervention": {
            "arm_group_label": "Repeated GnRHa", 
            "description": "0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 \u22653500 pg/ml, (ii) \u226518 follicles measuring \u226511 mm.", 
            "intervention_name": "triptorelin", 
            "intervention_type": "Drug", 
            "other_name": "Diphereline"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Triptorelin", 
                "Deslorelin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ovarian Hyperstimulation Syndrome", 
            "Luteinizing Hormone", 
            "Polycystic Ovarian Syndrome", 
            "Ovarian Yield", 
            "Ovarian Maturity"
        ], 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "contact": {
                "email": "chensl_92@163.com", 
                "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
                "phone": "+86-20-62787604"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510515"
                }, 
                "name": "Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University"
            }, 
            "investigator": {
                "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Repeated Injection of GnRH Agonist for Triggering Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol", 
        "overall_contact": {
            "email": "chensl_92@163.com", 
            "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
            "phone": "+86-20-62787604"
        }, 
        "overall_official": [
            {
                "affiliation": "Nanfang Hospital of Southern Medical University", 
                "last_name": "Shi-Ling Chen, M.D., Ph.D.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Nanfang Hospital of Southern Medical University", 
                "last_name": "Xin Chen, M.D., Ph.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "clinical pregnancy rate per transfer cycle", 
                "safety_issue": "Yes", 
                "time_frame": "1month post embryo transfer"
            }, 
            {
                "measure": "numbers of patients having OHSS", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks post trigger with repeated GnRHa"
            }, 
            {
                "description": "Oocyte yield was defined as the ratio of the total number of collected oocytes to the number of follicles measuring \u226510 mm on the day of oocyte retrieval.", 
                "measure": "oocyte yield", 
                "safety_issue": "Yes", 
                "time_frame": "oocyte retrieval day (34 to 38 hours post the first trigger with GnRHa)"
            }, 
            {
                "description": "Oocyte maturity was defined as the ratio of metaphase II (MII) oocytes to the number of collected oocytes in the patients undergoing with ICSI.", 
                "measure": "Oocyte maturity", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours post oocyte retrieval day"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022241"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Nanfang Hospital of Southern Medical University", 
            "investigator_full_name": "Chenshiling", 
            "investigator_title": "Professor, M.D., Ph.D.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "serum luteinizing hormone level 12 hours post first trigger", 
                "safety_issue": "Yes", 
                "time_frame": "12 hours post trigger with the first injection of GnRHa"
            }, 
            {
                "measure": "serum luteinizing hormone level 24 hours post first trigger", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours post the first injection of GnRHa"
            }, 
            {
                "description": "Fertilization rate was defined as the ratio of normal fertilized oocytes (2PNs) to the number of oocytes used for fertilization (i.e. the denominator in IVF in calculating fertilization rate is all oocytes recovered, but in ICSI it is calculated using only the number of MII oocytes).", 
                "measure": "fertilization rate", 
                "safety_issue": "Yes", 
                "time_frame": "48 hours post IVF/ICSI"
            }, 
            {
                "measure": "implantation rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 month post embryo transfer"
            }
        ], 
        "source": "Nanfang Hospital of Southern Medical University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Natural Science Foundation of China", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Comprehensive Strategic Sciences Cooperation Projects of Guangdong Province and Chinese Academy", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Guangzhou Science and Technology Program key projects", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Key Basic Research Development Plan of China", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Chenshiling", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}